SHAPE-ENDO：肥胖与早期子宫内膜癌患者的多模式术前优化 (SHAPE-ENDO)
2026年6月6日 更新者：Jorge García Fernández、Hospital Universitari de Bellvitge
SHAPE-ENDO（司美格鲁肽+激素疗法与预康复在子宫内膜癌中的应用）：针对非典型子宫内膜增生或早期子宫内膜癌且BMI≥35患者的代谢与手术优化的前瞻性观察研究。
SHAPE-ENDO 是一项在贝尔维特大学医院进行的前瞻性观察性研究，旨在评估针对肥胖（BMI≥35）合并非典型子宫内膜增生或早期子宫内膜癌女性的多模式术前优化策略。参与者接受标准护理干预，包括索马鲁肽治疗、左炔诺孕酮宫内节育器（联合或不联合口服孕激素）、结构化营养和运动计划，以及定期子宫内膜监测。
该研究旨在评估这种多模式策略是否能改善代谢健康、促进体重减轻、提高微创手术的适用性，同时在优化期间保持肿瘤安全性。
参与者接受为期6-12个月的随访，监测人体测量和代谢参数、组织学反应、生活质量及治疗依从性。所有干预措施均为常规临床护理的一部分。本研究结果可能为未来评估肥胖合并早期子宫内膜癌患者代谢优化策略的比较性试验提供参考。
研究概览
地位
尚未招聘
详细说明
肥胖是子宫内膜癌的主要风险因素，与手术复杂性增加、围手术期并发症增多以及微创手术资格降低相关。 在重度肥胖患者中，死亡率通常受代谢合并症而非癌症进展的影响。 因此，术前旨在改善代谢健康和功能状态的策略可能具有重要的临床意义。
激素疗法，如左炔诺孕酮宫内缓释系统和全身性孕激素，通常用于控制特定非典型子宫内膜增生或早期子宫内膜样癌患者的病情。 与此同时，胰高血糖素样肽-1受体激动剂（包括司美格鲁肽）已显示出显著的减重和心血管代谢益处。 结合药物治疗、营养优化和结构化运动计划的多模式预康复方法，可能改善手术准备情况和整体健康状况。
SHAPE-ENDO 是一项在贝尔维特大学医院开展的前瞻性观察队列研究。 该研究评估了一种多模式术前优化策略，包括使用司美格鲁肽进行药物体重管理、使用左炔诺孕酮宫内缓释系统联合或不联合口服孕激素进行激素子宫内膜治疗，以及包括监督饮食咨询和运动计划在内的生活方式干预。 患者根据常规临床实践接受定期的临床随访，包括代谢监测、影像学检查和子宫内膜取样。
该研究旨在评估这种多模式优化策略在肥胖和早期子宫内膜疾病女性中的可行性和临床影响。 结果包括代谢和人体测量学变化、组织学反应、生活质量以及微创手术资格。 数据通过电子病历、实验室检测、影像学研究和经过验证的患者报告结果问卷收集。 该研究已获得机构伦理委员会批准，仅涉及标准护理干预。
研究类型
介入性
注册 (估计的)
80
阶段
- 第四阶段
联系人和位置
本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。
学习联系方式
- 姓名：Jorge Garcia Fernandez, MD
- 电话号码：+34 622595644
- 邮箱：jorgarciafernan@gmail.com
参与标准
研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
不
研究人群
接受手术前多模式代谢-激素预康复治疗的体重指数≥35公斤/平方米、患有早期低/中危子宫内膜样子宫内膜癌或非典型增生/EIN的成年女性。
描述
入选标准：
- 女性，年龄≥18岁。
- 经组织学确诊的非典型子宫内膜增生/EIN或低风险子宫内膜样子宫内膜癌（G1-G2），局限于子宫体。
- 根据ESGO-ESTRO-ESP 2025分类为低/中风险；术前分期为IA1、IA2或IB期。
- 淋巴血管间隙浸润阴性或局灶性（如有数据）。
- 分子亚型：POLE突变型、p53野生型、错配修复缺陷型或非特异性分子谱雌激素受体阳性型。
- 入组时体重指数≥35 kg/m²。
- 接受临时保守治疗并能遵循多模式优化策略。
- 有能力理解并签署知情同意书。
排除标准：
- FIGO分期为IA3、IC、II期或更高。
- 淋巴血管间隙浸润阳性。
- 高风险分子亚型：p53突变型或非特异性分子谱雌激素受体阴性型。
- 非子宫内膜样组织学类型（浆液性、透明细胞、癌肉瘤、混合型等）。
- 转移性或子宫外疾病。
- GLP-1受体激动剂或孕激素类药物禁忌症。
- 既往胰腺炎、多发性内分泌腺瘤2型、甲状腺髓样癌病史。
- 参与其他药物临床试验。
- 研究者判断可能影响安全性或依从性的任何状况。
学习计划
本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。
研究是如何设计的？
设计细节
- 主要用途：治疗
- 分配：随机化
- 介入模型：并行分配
- 屏蔽：无（打开标签）
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器：Arm A - Standard Immediate Surgery
Participants randomized to the control arm will undergo standard immediate surgical treatment according to the institutional protocol of Hospital Universitari de Bellvitge. Surgery will usually include hysterectomy with bilateral salpingo-oophorectomy, sentinel lymph node assessment when indicated and feasible, and minimally invasive or robotic approach whenever technically possible according to clinical judgment. Intervention: Procedure/Surgery - Standard Immediate Surgery Standard surgical management according to institutional practice for atypical endometrial hyperplasia/endometrial intraepithelial neoplasia or early-stage low-risk endometrioid endometrial cancer. Perioperative outcomes, surgical approach, conversion to laparotomy, estimated blood loss, operative time, hospital stay, transfusion, sentinel lymph node detection, intraoperative complications, and 30-day postoperative complications graded according to Clavien-Dindo will be recorded. |
Standard surgical treatment according to the institutional protocol of Hospital Universitari de Bellvitge for atypical endometrial hyperplasia/endometrial intraepithelial neoplasia or early-stage low-risk endometrioid endometrial cancer.
Surgery will usually include hysterectomy with bilateral salpingo-oophorectomy, sentinel lymph node assessment when indicated and feasible, and a minimally invasive or robotic approach whenever technically possible according to clinical judgment.
Surgical approach, operative time, estimated blood loss, conversion to laparotomy, transfusion, hospital stay, intraoperative complications, 30-day postoperative complications, readmission, and sentinel lymph node detection will be recorded.
其他名称：
|
|
实验性的：Arm B - Experimental: SHAPE-ENDO Multimodal Strategy Before Surgery
Participants randomized to the experimental arm will receive the SHAPE-ENDO multimodal pre-surgical optimization strategy before surgery. The strategy includes semaglutide/Wegovy®, levonorgestrel-releasing intrauterine device/Mirena® with or without oral medroxyprogesterone acetate/Progevera®, structured nutritional intervention, adapted physical exercise, and scheduled oncologic surveillance. The strategy will last 28 weeks initially and may be extended up to 54 weeks if there is clinical, metabolic, or anthropometric benefit, adequate tolerance, and no tumor progression. Intervention: Drug - Semaglutide / Wegovy® Weekly subcutaneous semaglutide administered according to approved labeling, clinical indication, tolerance, and endocrinology assessment, with standard dose escalation up to the tolerated therapeutic dose. Dose, adherence, tolerability, adverse events, and reasons for dose modification or discontinuation will be recorded. Intervention: Device - Levonorgestrel-Releasing I |
由临床营养团队监督的个性化低热量饮食计划，作为标准肥胖和代谢管理的一部分。
该计划包括基于基础代谢需求的卡路里限制，在特定病例中可选择为期4-6周的极低卡路里饮食（VLCD）。
随访在定期门诊就诊时进行，记录体重、BMI、腰围和依从性。
此干预是常规临床护理的一部分，非实验性分配；结果进行前瞻性记录。
其他名称：
一项旨在改善功能能力、有氧耐受性和手术适应性的结构化体育锻炼计划。
该计划包括每周监督或半监督的课程，结合有氧和力量训练，通常每周3次，每次30-45分钟，根据基线表现进行调整。
该干预是肥胖患者手术准备常规临床护理的一部分，并非实验性分配。
前瞻性收集有关依从性、耐受性和功能结果的数据
其他名称：
在基线和随访间隔（通常为14周和28-54周）进行预定的组织学监测，以评估局部肿瘤状态，包括完全缓解、稳定或进展。
程序包括门诊子宫内膜活检，根据临床指征可选宫腔镜检查。
这些评估构成对非典型子宫内膜增生或早期子宫内膜样癌进行保守治疗患者的标准临床护理部分，并非实验性分配。
前瞻性记录数据以评估疾病演变和手术适宜性。
其他名称：
作为常规临床护理的一部分，通过盆腔磁共振成像和经阴道超声进行影像学评估，以评估子宫疾病、肌层浸润、附件状况和治疗反应。
影像学检查通常在基线时进行以确认分期，并在临床需要时在随访期间进行。
这些影像学检查方法按照标准临床指南使用，并非实验性分配；前瞻性地收集结果以评估疾病稳定性和手术规划。
其他名称：
Weekly subcutaneous semaglutide/GLP-1 receptor agonist therapy administered according to approved labeling, clinical indication, patient tolerance, and endocrinology assessment, with standard dose escalation up to the tolerated therapeutic dose.
The intervention is used for weight loss and metabolic optimization in participants with severe obesity.
Dose, adherence, tolerability, and reasons for dose modification or discontinuation will be recorded prospectively.
其他名称：
Local hormonal therapy using a 52-mg levonorgestrel-releasing intrauterine system placed at baseline or within 14 days after baseline, with ultrasound confirmation of correct placement.
The LNG-IUD is used within the protocolized SHAPE-ENDO strategy according to clinical indication, approved labeling, current guidelines, and physician judgment, for local disease control in atypical endometrial hyperplasia/endometrial intraepithelial neoplasia or early-stage, low-risk endometrioid endometrial cancer.
Tolerability, continuation, adverse events, and local histological response will be recorded prospectively.
其他名称：
Systemic hormonal therapy prescribed according to clinical criteria to support local disease control in atypical endometrial hyperplasia or early-stage endometrioid carcinoma.
Typical regimens include medroxyprogesterone acetate (400-600 mg/day) or megestrol acetate (160-320 mg/day).
Therapy is initiated or escalated when indicated based on tumor burden or suboptimal response to LNG-IUD.
Oral progestins may be used within the protocolized SHAPE-ENDO strategy according to clinical indication, approved labeling, current guidelines, and physician judgment.
Use, dosing, tolerance, and outcomes will be recorded prospectively.
其他名称：
|
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Recruitment Rate
大体时间：From study opening to end of recruitment, up to 36 months.
|
Number of participants enrolled per month during the active recruitment period.
This outcome will assess the feasibility of recruiting eligible participants with atypical endometrial hyperplasia/endometrial intraepithelial neoplasia or low-risk endometrioid endometrial cancer and BMI ≥40 kg/m² into a pilot randomized clinical trial.
|
From study opening to end of recruitment, up to 36 months.
|
|
Acceptance of Randomization Rate
大体时间：At baseline, before randomization.
|
Proportion of eligible participants who agree to participate in the trial and accept random assignment to either standard immediate surgery or the SHAPE-ENDO multimodal pre-surgical optimization strategy.
|
At baseline, before randomization.
|
|
Participant Retention Rate
大体时间：From randomization to surgery and 30 days postoperatively, up to 14 months.
|
Proportion of randomized participants who complete the planned follow-up required for the main pilot analysis, including surgical treatment and 30-day postoperative assessment, or completion of the assigned intervention period when applicable.
|
From randomization to surgery and 30 days postoperatively, up to 14 months.
|
|
Adherence to the Assigned Intervention
大体时间：From randomization to surgery and 30 days postoperatively, up to 14 months.
|
Proportion of randomized participants who comply with the main procedures planned in their assigned arm.
In the control arm, this includes undergoing standard immediate surgery and postoperative follow-up.
In the SHAPE-ENDO arm, this includes adherence to the multimodal strategy, scheduled visits, oncologic surveillance, and planned reassessment.
|
From randomization to surgery and 30 days postoperatively, up to 14 months.
|
|
Completion of the SHAPE-ENDO Multimodal Strategy
大体时间：From randomization to week 28 or week 54.
|
Proportion of participants randomized to the SHAPE-ENDO arm who complete the planned multimodal pre-surgical optimization strategy until the week 28 reassessment and, when applicable, until week 54.
|
From randomization to week 28 or week 54.
|
|
Proportion of SHAPE-ENDO Participants Reaching Surgery Without Tumor Progression
大体时间：From randomization to surgery, up to 54 weeks.
|
Proportion of participants randomized to the SHAPE-ENDO arm who undergo surgery after the pre-surgical optimization period without histological, radiological, or clinical evidence of tumor progression.
|
From randomization to surgery, up to 54 weeks.
|
|
Incidence of Serious Adverse Events, Tumor Progression, and Study Discontinuation
大体时间：From randomization to surgery and 30 days postoperatively, up to 14 months.
|
Frequency of serious adverse events, tumor progression during the optimization period, and reasons for discontinuation or withdrawal from the study.
Adverse events will be recorded prospectively and classified according to CTCAE v5.0 when applicable.
These events will be described overall and by randomized arm when applicable.
|
From randomization to surgery and 30 days postoperatively, up to 14 months.
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Perioperative Morbidity
大体时间：At surgery and up to 30 days postoperatively.
|
Proportion of participants with intraoperative complications and/or clinically relevant postoperative complications within 30 days after surgery, compared between the standard immediate surgery arm and the SHAPE-ENDO arm.
Postoperative complications will be classified according to the Clavien-Dindo classification, with clinically relevant complications defined as Clavien-Dindo grade ≥II
|
At surgery and up to 30 days postoperatively.
|
|
Surgical Approach
大体时间：At surgery.
|
Proportion of participants undergoing minimally invasive surgery, robotic surgery, conventional laparoscopy, or laparotomy, compared between the standard immediate surgery arm and the SHAPE-ENDO arm.
|
At surgery.
|
|
Conversion to Laparotomy
大体时间：At surgery.
|
Proportion of participants requiring conversion from minimally invasive surgery to laparotomy, compared between the standard immediate surgery arm and the SHAPE-ENDO arm.
|
At surgery.
|
|
Operative Time
大体时间：At surgery.
|
Duration of surgery measured in minutes, from skin incision to skin closure, compared between the standard immediate surgery arm and the SHAPE-ENDO arm.
|
At surgery.
|
|
Estimated Blood Loss
大体时间：At surgery.
|
Estimated intraoperative blood loss measured in milliliters, compared between the standard immediate surgery arm and the SHAPE-ENDO arm.
|
At surgery.
|
|
Length of Hospital Stay
大体时间：From surgery to hospital discharge, up to 30 days.
|
Number of days from surgery to hospital discharge, compared between the standard immediate surgery arm and the SHAPE-ENDO arm.
|
From surgery to hospital discharge, up to 30 days.
|
|
Need for Blood Transfusion
大体时间：At surgery and up to 30 days postoperatively.
|
Proportion of participants requiring perioperative blood transfusion, compared between the standard immediate surgery arm and the SHAPE-ENDO arm
|
At surgery and up to 30 days postoperatively.
|
|
Sentinel Lymph Node Detection Rate
大体时间：At surgery.
|
Proportion of participants in whom sentinel lymph node mapping is successful, including unilateral and bilateral detection rates when sentinel lymph node assessment is performed.
Detection rates will be described and compared between the standard immediate surgery arm and the SHAPE-ENDO arm.
|
At surgery.
|
|
Histological Response in the SHAPE-ENDO Arm
大体时间：Baseline to week 14, week 28, and, if applicable, week 54.
|
Proportion of participants in the SHAPE-ENDO arm with complete response, stable disease, or tumor progression during the pre-surgical optimization period.
Complete response is defined as absence of endometrioid carcinoma or atypical hyperplasia in endometrial biopsy.
Stable disease is defined as persistence of the lesion without progression in grade or stage.
Progression is defined as progression from atypical endometrial hyperplasia/endometrial intraepithelial neoplasia to endometrioid endometrial carcinoma, increase to grade 3, high-risk histology, or extension beyond the uterine corpus.
|
Baseline to week 14, week 28, and, if applicable, week 54.
|
|
Time to Optimization in the SHAPE-ENDO Arm
大体时间：From randomization to week 28 or week 54
|
Time from randomization to multidisciplinary committee decision indicating that sufficient clinical, metabolic, anthropometric, and oncologic optimization has been achieved to proceed to surgery.
|
From randomization to week 28 or week 54
|
|
Rate of Surgery After SHAPE-ENDO Optimization
大体时间：From randomization to surgery, up to 54 weeks.
|
Proportion of participants randomized to the SHAPE-ENDO arm who undergo surgery after the pre-surgical optimization strategy.
|
From randomization to surgery, up to 54 weeks.
|
|
Change in Glycated Hemoglobin
大体时间：Baseline to 6 months and baseline to 12 months.
|
Change from baseline in glycated hemoglobin, measured as HbA1c percentage using standard clinical laboratory assays.
Changes over time will be described within each arm and compared between the standard immediate surgery arm and the SHAPE-ENDO arm.
|
Baseline to 6 months and baseline to 12 months.
|
|
Change in Fasting Plasma Glucose
大体时间：Baseline to 6 months and baseline to 12 months.
|
Change from baseline in fasting plasma glucose concentration, measured in mg/dL using standard laboratory assays.
Changes over time will be described within each arm and compared between both randomized arms.
|
Baseline to 6 months and baseline to 12 months.
|
|
Change in Insulinemia and HOMA-IR
大体时间：Baseline to 6 months and baseline to 12 months.
|
Change from baseline in fasting insulin concentration and HOMA-IR, when available.
Changes over time will be described within each arm and compared between both randomized arms.
|
Baseline to 6 months and baseline to 12 months.
|
|
Change in FIB-4 Index
大体时间：Baseline to 6 months and baseline to 12 months.
|
Change from baseline in fibrosis-4 index, calculated using age, AST, ALT, and platelet count.
Changes over time will be described within each arm and compared between both randomized arms.
|
Baseline to 6 months and baseline to 12 months.
|
|
Change in Lipid Profile
大体时间：Baseline to 6 months and baseline to 12 months.
|
Change from baseline in triglycerides, LDL cholesterol, and HDL cholesterol measured using standard laboratory lipid panel testing.
Changes over time will be described within each arm and compared between both randomized arms.
|
Baseline to 6 months and baseline to 12 months.
|
|
Change in Blood Pressure
大体时间：Baseline to 6 months and baseline to 12 months.
|
Change from baseline in systolic and diastolic blood pressure, measured in mmHg during scheduled clinical visits.
Changes over time will be described within each arm and compared between both randomized arms.
|
Baseline to 6 months and baseline to 12 months.
|
|
Change in C-Reactive Protein
大体时间：Baseline to 6 months and baseline to 12 months.
|
Change from baseline in serum C-reactive protein concentration, measured in mg/L using standard laboratory assays.
Changes over time will be described within each arm and compared between both randomized arms.
|
Baseline to 6 months and baseline to 12 months.
|
|
Change in Body Weight and BMI
大体时间：Baseline to 6 months and baseline to 12 months.
|
Absolute and percentage change from baseline in body weight and body mass index.
Changes over time will be described within each arm and compared between both randomized arms.
|
Baseline to 6 months and baseline to 12 months.
|
|
Change in Waist Circumference
大体时间：Baseline to 6 months and baseline to 12 months.
|
Change from baseline in waist circumference, measured in centimeters.
Changes over time will be described within each arm and compared between both randomized arms.
|
Baseline to 6 months and baseline to 12 months.
|
|
Change in Visceral Adiposity by MRI
大体时间：Baseline to week 28 and, if applicable, week 54.
|
Absolute and percentage change from baseline in visceral adiposity measured by pelvic MRI according to the predefined radiologic measurement protocol.
Changes over time will be described within each arm and compared between both randomized arms.
|
Baseline to week 28 and, if applicable, week 54.
|
|
Change in Body Composition by Bioelectrical Impedance Analysis
大体时间：Baseline to week 28 and, if applicable, week 54.
|
Change from baseline in body composition parameters measured by bioelectrical impedance analysis.
Changes over time will be described within each arm and compared between both randomized arms.
|
Baseline to week 28 and, if applicable, week 54.
|
|
Change in Health-Related Quality of Life Score - SF-36
大体时间：Baseline to 6 months, 12 months, and during long-term follow-up up to 5 years.
|
Change from baseline in health-related quality of life assessed using the Short Form-36 Health Survey.
Scores range from 0 to 100, with higher scores indicating better health-related quality of life.
Changes over time will be described within each arm and compared between both randomized arms.
|
Baseline to 6 months, 12 months, and during long-term follow-up up to 5 years.
|
|
Change in Quality of Life Score - EORTC QLQ-C30
大体时间：Baseline to 6 months, 12 months, and during long-term follow-up up to 5 years.
|
Change from baseline in quality of life assessed using the EORTC QLQ-C30 questionnaire.
Scores range from 0 to 100 according to EORTC scoring guidelines.
Changes over time will be described within each arm and compared between both randomized arms.
|
Baseline to 6 months, 12 months, and during long-term follow-up up to 5 years.
|
|
Overall Survival
大体时间：From randomization up to 5 years.
|
Time from randomization to death from any cause.
Participants alive at the end of follow-up will be censored at the date of last contact.
|
From randomization up to 5 years.
|
|
Cancer-Specific Survival
大体时间：From randomization up to 5 years.
|
Time from randomization to death from endometrial cancer.
Participants alive or deceased from causes unrelated to endometrial cancer will be censored according to the statistical analysis plan.
|
From randomization up to 5 years.
|
|
Recurrence-Free Survival
大体时间：From randomization up to 5 years.
|
Time from randomization to first documented recurrence of endometrial cancer.
Recurrence may be defined by histological, radiological, or clinical evidence according to standard follow-up criteria.
Participants without recurrence will be censored at the date of last available follow-up.
|
From randomization up to 5 years.
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 首席研究员：Jorge Garcia Fernandez、Hospital Universitari de Bellvitge
- 首席研究员：Lola Marti、Hospital Universitari de Bellvitge
出版物和有用的链接
负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。
一般刊物
- Minnella EM, Awasthi R, Loiselle SE, Agnihotram RV, Ferri LE, Carli F. Effect of Exercise and Nutrition Prehabilitation on Functional Capacity in Esophagogastric Cancer Surgery: A Randomized Clinical Trial. JAMA Surg. 2018 Dec 1;153(12):1081-1089. doi: 10.1001/jamasurg.2018.1645.
- Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S, Ledermann J, Bosse T, Chargari C, Fagotti A, Fotopoulou C, Gonzalez Martin A, Lax S, Lorusso D, Marth C, Morice P, Nout RA, O'Donnell D, Querleu D, Raspollini MR, Sehouli J, Sturdza A, Taylor A, Westermann A, Wimberger P, Colombo N, Planchamp F, Creutzberg CL. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer. 2021 Jan;31(1):12-39. doi: 10.1136/ijgc-2020-002230. Epub 2020 Dec 18.
- Davies M, Faerch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, Rosenstock J, Shimomura I, Viljoen A, Wadden TA, Lingvay I; STEP 2 Study Group. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021 Mar 13;397(10278):971-984. doi: 10.1016/S0140-6736(21)00213-0. Epub 2021 Mar 2.
- Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, Lingvay I, Mosenzon O, Rosenstock J, Rubio MA, Rudofsky G, Tadayon S, Wadden TA, Dicker D; STEP 4 Investigators. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021 Apr 13;325(14):1414-1425. doi: 10.1001/jama.2021.3224.
- Akesson A, Wolmesjo N, Adok C, Milsom I, Dahm-Kahler P. Lymphadenectomy, obesity and open surgery are associated with surgical complications in endometrial cancer. Eur J Surg Oncol. 2021 Nov;47(11):2907-2914. doi: 10.1016/j.ejso.2021.06.034. Epub 2021 Jul 1.
- Iavazzo C, Gkegkes ID. Conservative management of patients with endometrial intraepithelial neoplasia (EIN): Factors that could affect response and pregnancy rates. Turk J Med Sci. 2022 Jun;52(3):870. doi: 10.55730/1300-0144.5384. Epub 2022 Jun 16. No abstract available.
- Cui J, Zhao YC, She LZ, Wang TJ. Comparative effects of progestin-based combination therapy for endometrial cancer or atypical endometrial hyperplasia: a systematic review and network meta-analysis. Front Oncol. 2024 May 3;14:1391546. doi: 10.3389/fonc.2024.1391546. eCollection 2024.
- Laurelli G, Falcone F, Gallo MS, Scala F, Losito S, Granata V, Cascella M, Greggi S. Long-Term Oncologic and Reproductive Outcomes in Young Women With Early Endometrial Cancer Conservatively Treated: A Prospective Study and Literature Update. Int J Gynecol Cancer. 2016 Nov;26(9):1650-1657. doi: 10.1097/IGC.0000000000000825.
- Fan Z, Li H, Hu R, Liu Y, Liu X, Gu L. Fertility-Preserving Treatment in Young Women With Grade 1 Presumed Stage IA Endometrial Adenocarcinoma: A Meta-Analysis. Int J Gynecol Cancer. 2018 Feb;28(2):385-393. doi: 10.1097/IGC.0000000000001164.
- Marnach ML, Butler KA, Henry MR, Hutz CE, Langstraat CL, Lohse CM, Casey PM. Oral Progestogens Versus Levonorgestrel-Releasing Intrauterine System for Treatment of Endometrial Intraepithelial Neoplasia<sup/> J Womens Health (Larchmt). 2017 Apr;26(4):368-373. doi: 10.1089/jwh.2016.5774. Epub 2016 Nov 30.
- Bourou MZ, Matsas A, Valsamakis G, Vlahos N, Panoskaltsis T. The Potential Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists as a Type of Conservative Treatment of Endometrial Cancer in Women of Reproductive Age: A Review of the Literature and a Call for Study. Cureus. 2024 Sep 18;16(9):e69678. doi: 10.7759/cureus.69678. eCollection 2024 Sep.
- Toliver JC, Divino V, Ng CD, Wang J. Real-World Weight Loss Among Patients Initiating Semaglutide 2.4 mg and Enrolled in WeGoTogether, a Digital Self-Support Application. Adv Ther. 2025 Oct;42(10):5010-5022. doi: 10.1007/s12325-025-03325-1. Epub 2025 Aug 6.
- Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, Jodar E, Kandler K, Rigas G, Wadden TA, Wharton S; STEP 5 Study Group. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022 Oct;28(10):2083-2091. doi: 10.1038/s41591-022-02026-4. Epub 2022 Oct 10.
- von Gruenigen VE, Tian C, Frasure H, Waggoner S, Keys H, Barakat RR. Treatment effects, disease recurrence, and survival in obese women with early endometrial carcinoma : a Gynecologic Oncology Group study. Cancer. 2006 Dec 15;107(12):2786-91. doi: 10.1002/cncr.22351.
- Vargiu V, Rosati A, Capozzi VA, Sozzi G, Gioe A, Berretta R, Chiantera V, Scambia G, Fanfani F, Cosentino F. Impact of Obesity on Sentinel Lymph Node Mapping in Patients with apparent Early-Stage Endometrial Cancer: The ObeLyX study. Gynecol Oncol. 2022 May;165(2):215-222. doi: 10.1016/j.ygyno.2022.03.003. Epub 2022 Mar 18.
- Habo YK, Habo NK, Elsayed AAR, Basson MD. Risk factors for postoperative complications following hysterectomy in endometrial cancer patients: A systematic review. J Gynecol Obstet Hum Reprod. 2025 Sep;54(7):102964. doi: 10.1016/j.jogoh.2025.102964. Epub 2025 Apr 30.
- Gallos ID, Yap J, Rajkhowa M, Luesley DM, Coomarasamy A, Gupta JK. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol. 2012 Oct;207(4):266.e1-12. doi: 10.1016/j.ajog.2012.08.011. Epub 2012 Aug 10.
- Aune D, Navarro Rosenblatt DA, Chan DS, Vingeliene S, Abar L, Vieira AR, Greenwood DC, Bandera EV, Norat T. Anthropometric factors and endometrial cancer risk: a systematic review and dose-response meta-analysis of prospective studies. Ann Oncol. 2015 Aug;26(8):1635-48. doi: 10.1093/annonc/mdv142. Epub 2015 Mar 19.
- Concin N, Matias-Guiu X, Cibula D, Colombo N, Creutzberg CL, Ledermann J, Mirza MR, Vergote I, Abu-Rustum NR, Bosse T, Chargari C, Espenel S, Fagotti A, Fotopoulou C, Gatius S, Gonzalez-Martin A, Lax S, Levy B, Lorusso D, Macchia G, Marth C, Morice P, Oaknin A, Raspollini MR, Schwameis R, Sehouli J, Sturdza A, Taylor A, Westermann A, Wimberger P, Planchamp F, Nout RA. ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: update 2025. Lancet Oncol. 2025 Aug;26(8):e423-e435. doi: 10.1016/S1470-2045(25)00167-6.
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (估计的)
2027年1月1日
初级完成 (估计的)
2031年4月1日
研究完成 (估计的)
2035年1月1日
研究注册日期
首次提交
2025年11月23日
首先提交符合 QC 标准的
2026年3月5日
首次发布 (实际的)
2026年3月10日
研究记录更新
最后更新发布 (实际的)
2026年6月10日
上次提交的符合 QC 标准的更新
2026年6月6日
最后验证
2026年6月1日
更多信息
与本研究相关的术语
关键字
其他相关的 MeSH 术语
- 泌尿生殖系统疾病
- 生殖器疾病
- 营养失调
- 泌尿生殖系统肿瘤
- 按部位分类的肿瘤
- 女性泌尿生殖系统疾病
- 女性泌尿生殖系统疾病和妊娠并发症
- 营养过剩
- 体重
- 子宫疾病
- 生殖器疾病，女性
- 生殖器肿瘤，女性
- 子宫肿瘤
- 病理状况、体征和症状
- 营养代谢疾病
- 体征和症状
- 肿瘤
- 超重
- 肥胖
- 子宫内膜肿瘤
- 子宫内膜增生
- 药物的生理作用
- 荷尔蒙
- 激素、激素替代品和激素拮抗剂
- 医疗保健质量，访问和评估
- 运动活动
- 移动
- 肌肉骨骼生理现象
- 肌肉骨骼和神经生理现象
- 调查技术
- 流行病学方法
- 疗法
- 诊断技术和程序
- 诊断
- 手术程序，手术
- 药物疗法
- 微创手术程序
- 药理作用
- 化学作用和用途
- 数据收集
- 医疗保健评估机制
- 医疗保健质量
- 公共卫生
- 环境与公共卫生
- 物理治疗方式
- 多环化合物
- 怀孕
- 怀孕
- 类固醇
- 融合环化合物
- 病人护理
- 运动疗法
- 康复
- 护理
- 病人护理的连续性
- 诊断技术，手术
- 内窥镜检查
- 化学技术，分析
- 频谱分析
- 流行病学测量
- 怀孕
- 怀孕
- 身体调节，人类
- 泌尿生殖器手术程序
- 锻炼
- 妇科手术程序
- 产科手术程序
- Medroxyprogesterone
- 羟孕酮
- 孕酮
- MEGENTROL
- 诊断技术，产科和妇科
- 激素替代疗法
- 醋酸甲地孕酮
- 醋酸甲羟孕酮
- 孕激素
- 磁共振光谱
- semaglutide
- 抵抗训练
- 营养评估
- 子宫切除术
- 宫腔镜检查
- 雌激素替代疗法
其他研究编号
- SHAPE-ENDO
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)？
未定
药物和器械信息、研究文件
研究美国 FDA 监管的药品
不
研究美国 FDA 监管的设备产品
不
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.